Paclitaxel, Docetaxel, Irinotecan

DRUG2 trials

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd.

Conditions

Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based ChemotherapySecond-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT06649292

Shanghai Hengrui Pharmaceutical Co., Ltd.Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2024-11-22End: 2028-03-20Target: 524Updated: 2026-05-15

FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.

Not yet recruitingNCT07790380

Jiangsu HengRui Medicine Co., Ltd.Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy

Start: 2026-10-10End: 2029-06-30Target: 480Updated: 2026-08-27